Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

"Not all GLP-1s are the same." Retatrutide, the 'King Kong' drug to mimic bariatric surgery Eli Lilly isn't pivoting away from weekly weight loss injections entirely. It's also working on another ...

Can Lilly immunize retatrutide from compounded copies? Will the district court second guess – much less overturn – FDA’s decision to regulate this GLP-1 as a drug? Although perhaps a bit ...

Originally, the retatrutide study was supposed to come out in February 2026, but now, it has been moved up months ahead of schedule, coming out later this year instead. Lilly’s tests here are ...

Notably, Eli Lilly said it plans to report late-stage data on its next-generation obesity drug retatrutide later this year, a few months earlier than expected. Retatrutide works differently from ...